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Minor groove alkylating agents are a relatively new class of
compounds that have shown high anti-tumour activity in experi-
mental systems (Martin et al, 1981; Li et al, 1992; D’Alessio et al,
1994; D’Incalci and Sessa, 1997). The interaction of these
compounds with DNA has been studied in detail and it has been
found that compounds possessing anti-tumour activity were able
to alkylate the N3 of adenines lying in the minor groove with a
very high sequence specificity (Hurley et al, 1984; Broggini et al,
1991, 1995). Structure-activity studies on a series of distamycin
derivatives have shown that changes in the alkylation potency,
without altering the sequence specificity, correlates with the cyto-
toxicity observed in vitro (Marchini et al, 1997), and that the loss
of alkylation ability was associated with loss of in vitro cytotoxi-
city (Marchini et al, 1997). Recently, PNU 151807, a new deriva-
tive of the non-covalent minor groove-interacting compound,
distamycin A, has been synthesized. This compound, while able to
non-covalently interact with AT-rich regions in DNA, was devoid
of any DNA alkylating ability but, interestingly, presented a very
high anti-tumour activity both in vitro and in vivo (D’Alessio et al,
1994). The mechanism of action of this compound is not clear,
although the non-covalent minor groove interaction seems to be
essential at least for the in vivo anti-tumour activity.
The promising preclinical activity of this class of compounds
has stimulated studies aiming at identifying possible mechanisms
of resistance. It has been reported that, in cell lines defective in
proteins belonging to the nucleotide excision repair (NER)
pathway, tallimustine and CC1065 were only slightly less active
than in repair-proficient parental cell lines, while major groove
alkylating compounds such as melphalan or cis-diammine
dichloro platinum (II) (CDDP), were much more active in NER-
deficient cell lines (Damia et al, 1996b). Moreover, cell lines over-
expressing N3-adenine glycosylase had the same susceptibility to
tallimustine and CC1065 as parental cell lines (Damia et al,
1996a). Proteins belonging to the mismatch repair (MMR) family
play an important role in the resistance to alkylating agents and
recognition of certain types of major groove DNA damage (Karran
and Bignami, 1994; Branch et al, 1993, 1995; Fink et al, 1996;
Drummond et al, 1996). Loss of MMR is associated with the
development of resistance to monofunctional methylating agents
and tolerance to O6-methyl guanine adducts in DNA.
Furthermore, cell lines selected for resistance to the bifunctional
alkylating agent CDDP were shown to have lost MMR activity
(Drummond et al, 1996) and expression of hMLH1 (Brown et al,
1997). Restoration of MMR activity by re-expression of hMLH1
or hMSH2 by chromosome transfer confers increased sensitivity
to these agents (Koi et al., 1994; Aebi et al, 1996, 1997). For
different major groove alkylating agents, sensitivity of MMR-
deficient cell lines was reported to be lower than that observed in
mismatch-proficient cell lines (Koi et al, 1994; Anthoney et al,
1996; Aebi et al, 1997; Fink et al, 1997). We report here that minor
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Summary Mismatch DNA repair deficiency is associated with resistance to certain major groove alkylating agents including methylating
agents and cisplatin. We have now studied the relevance of mismatch repair alterations to the cytotoxicity induced by drugs which alkylate N3
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mutation in the hMLH1 gene, and a subline where hMLH1 expression is restored by chromosome 3 transfer (HCT-116+ch3). We have tested
three alkylating minor groove binders (tallimustine, carzelesin and CC1065) and one non-covalent minor groove binder (PNU 151807). The
HCT-116+ch3 subline was more sensitive than the parental line to the treatment with the three alkylating minor groove binders, while the non-
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groove alkylators is that two cisplatin-resistant sublines of the human ovarian adenocarcinoma cell line A2780 (A2780/CP70 and
A2780/MCP-1) are defective in hMLH1 expression and are more resistant to these agents than the parental mismatch repair proficient cells.
Furthermore, the restoration of hMLH1 activity in the A2780/CP70 cell line, by introduction of chromosome 3, was associated with an
increased sensitivity to the three alkylating minor groove binders. Again, the non-covalent minor groove binder was equally effective in
mismatch repair deficient and proficient clones. The data indicate that mismatch repair deficiency mediated by loss of hMLH1 expression is
associated not only with drug-resistance to major groove binders, but also to minor groove binders. However, loss of mismatch repair does
not mediate resistance to the non-covalent minor groove binder PNU 151807.
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groove alkylating agents are also susceptible to the status of MMR
and that loss of MMR activity is associated with a decreased
activity of all the tested alkylating minor groove binders. The non-
alkylating minor groove binder (MGB) PNU 151807 retained its
activity irrespective of the MMR status of the cell lines used.
MATERIALS AND METHODS
Cell lines
The hMLH1-deficient human colorectal adenocarcinoma cell
line HCT-116 and the subline into which a wild-type copy hMLH1
on chromosome 3 has been introduced by microcell fusion (HCT-
116+ch3) (Koi et al, 1994) were obtained from Dr G Marra,
Zurich. Both cell lines were grown in medium with 400 mg ml–1 of
G418 (Sigma). The human ovarian cancer cell line A2780 and two
CDDP-resistant sublines that have lost hMLH1 expression (Brown
et al, 1997) were grown in RPMI-1640 medium (GIBCO) supple-
mented with 10% fetal calf serum (FCS). A2780/CP70+ch3 clone
was obtained from CDDP-resistant, hMLH1-deficient cell line
A2780/CP70 by introducing chromosome 3 by microcell-
mediated chromosome transfer and was maintained in the same
medium as A2780/CP70 cells in the presence of 200 U ml–1 of
Hygromycin B (Boehringer, Italy).
Drugs and inhibition of colony formation
For clonogenic assay, cells were plated at 250 cells cm–2, treated
with different concentrations of compounds for 1 h and incubated
for 10–14 days in drug-free medium; the number of colonies
formed (roughly 50 cells) were counted after staining with
Giemsa.
Student’s  t-test analysis was performed to evaluate differences
between parental and chromosome transfected cell lines. IC50
values calculated from three independent experiments, each
consisting of at least three replicates, were used.
Tallimustine, CC1065, PNU 151807 and carzelesin (see
structure in Figure 1) were obtained from Pharmacia & Upjohn
(Nerviano, Italy), dissolved as stock solutions in dimethyl
sulphoxide (DMSO) and diluted in medium just prior to use.
CDDP was obtained from Bristol Myers Squibb and dissolved in
medium just prior to use. N-methyl-N-nitro-N-nitrosoguanosine
(MNNG) was purchased from Sigma, dissolved in DMSO and
subsequently diluted in medium.
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Figure 1 Chemical structure of the four minor groove binders
Table 1 IC50 for the different compounds tested in HCT116 and HCT116+ch3
cell lines
Compound HCT116 HCT116+ch3 Ratioa
CC1065 (pg ml–1) 33.8 ± 1.1 10.9 ± 1.0b 3.1
Carzelesin (ng ml–1) 2.6 ± 0.6 1.2 ± 0.4c 2.2
Tallimustine (ng ml–1) 59.1 ± 4.7 30.1 ± 2.9b 2
PNU 151807 (ng ml–1) 39.6 ± 1.7 35.1 ± 1.5 1.1
MNNG (mM) > 25 5.0 ± 1.9b > 5
CDDP (mM) 28.7 ± 3.7 12.7 ± 1.8b 2.3
The values are the mean ± s.d. of different experiments each consisting of at
least three replicates. aRatio between the IC50 values of HCT116 and
HCT116+ch3. bP ≤ 0.01 and cP ≤ 0.05 vs HCT116.
Table 2 IC50 values for the different compounds in A2780/CP70 and
A2780/CP70+ch3 cell lines
Compound A2780/CP70 A2780/CP70+ch3 Ratioa
CC1065 (pg ml–1) 95.5 ± 8.7 54.9 ± 8.6b 1.7
Carzelesin (ng ml–1) 5.2 ± 1.3 3.8 ± 0.1c 1.4
Tallimustine (ng ml–1) 124.5 ± 16.6 47.0 ± 11.0b 2.6
PNU 151807 (ng ml–1) 38.8 ± 2.8 40.1 ± 1.9 0.9
CDDP > 100 22.1 ± 6.3b > 4
The values are the mean ± s.d. of different experiments each consisting of at
least three replicates. aRatio between the IC50 values of A2780/CP70 and
A2780/CP70+ch3. bP ≤ 0.01 and cP ≤ 0.05 vs A2780/CP70.340 G Colella et al
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RESULTS
The cytotoxicity induced by tallimustine, carzelesin, CC1065 and
PNU 151807 was evaluated by clonogenic assay in HCT-116 and
HCT-116+ch3 cell lines (Figure 2), in comparison with CDDP and
MNNG, agents known to exert differential activity in these two
cell lines. As shown in Figure 2, the introduction of chromosome 3
in HCT-116 cells results in an increased sensitivity of the cells to
the treatment with the three alkylating minor groove binders, but
not to the non-covalent MGB PNU 151807, which was equally
active in both cell lines. The relative IC50 values calculated from
the curves shown in Figure 2 are reported in Table 1 where it can
be seen that the three alkylating MGB are approximately 2–3 times
less active in mismatch-deficient HCT-116 cells than in mismatch-
proficient HCT-116+ch3 cells. The difference in activity observed
after MNNG treatment was much greater.
The same experiments were performed in another well-
characterized system, the human ovarian cancer cell line
A2780 (mismatch-proficient) and two sublines, A2780/CP70 and
A2780/MCP-1 (obtained as CDDP-resistant clones from A2780
cells), which have been shown to lack expression of hMLH1
protein (Brown et al, 1997). In this system, the three alkylating
MGB showed, as in the colocarcinoma cell lines, less activity in
the two mismatch-deficient cell lines (Figure 3) and the degree of
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Figure 2 Effect of DNA mismatch repair deficiency due to loss of hMLH1 function on drug sensitivity determined by clonogenic assay. HCT 116 (u);
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resistance, calculated from the IC50 values, was similar to that
found for CDDP (data not shown). The non-alkylating MGB PNU
151807 was also more active in parental A2780 cells than in the
two CDDP-resistant clones. As shown in Figure 4 and Table 2,
re-expression of hMLH1 in these cells by chromosome transfer
partially restores sensitivity to CDDP and the three alkylating
MGB, but not to the non-alkylating MGB PNU 151807.
A2780/CP70 have previously been shown to have a number of
alterations that could affect drug sensitivity. The data presented
support a role for MMR in cytotoxicity of the alkylating MGB,
but the non-alkylating MGB PNU 151807 retained its activity
independently of the mismatch repair status.
DISCUSSION
The MMR system plays an important role in the control of
genomic integrity in cells (Karran and Bignami, 1994; Fishel and
Kolodner, 1995; Karran and Hampson, 1996). It has been reported
in different experimental systems that defects in MMR proteins
confer tolerance to methylating agents and also to some other
cytotoxic agents, including CDDP (Anthoney et al, 1996, Fink
et al, 1996, 1997). Furthermore, selection of CDDP-resistant cell
lines can result in loss of the expression of these proteins
(Drummond et al, 1996; Brown et al, 1997). Recently, it has been
reported that biopsies of residual disease from human ovarian
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Figure 3 Clonogenic sensitivities of parental A2780 and mismatch repair-deficient CDDP-resistant subline A2780/CP70 and A2780/MCP1. A2780 (u);
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tumours after chemotherapy showed a higher incidence of loss of
hMLH1 expression compared to untreated tumours (Brown et al,
1997).
If loss of MMR is indeed relevant for clinical resistance to
chemotherapy, this has an important implication for the selection
and use of new therapeutic compounds. Thus, compounds not
requiring MMR to mediate toxicity will have a different mecha-
nism of action and will have activity in MMR-deficient tumours.
In the present study we show that minor groove alkylating
agents, a new emerging class of anticancer agents, also utilize
MMR to mediate their tumour cell killing. This is a new finding
which increases the number of DNA lesions potentially recognized
by the MMR proteins. It should be noted that, in contrast to
CDDP which induces a relatively high number of drug adducts in
the major groove of DNA, all the three alkylating MGB tested
produced only a limited number of DNA lesions (Hurley et al,
1984; Broggini et al, 1991, 1995). This is particularly true for
tallimustine which is able to alkylate the N3 of adenine only when
present in the hexamer sequence 5¢-TTTTGA (Broggini et al,
1995). Despite the different number of DNA lesions induced,
the three alkylating MGB showed roughly the same ratio of
activity between mismatch-proficient and mismatch-deficient
cells observed for CDDP. While it does appear that the
MMR-associated resistance does not apply to all the major groove
alkylating agents (as reported for example for melphalan, which
was able to induce the same cytotoxicity in HCT-116 and
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Figure 4 Clonogenic survival curves in CDDP-resistant ovarian cancer cell lines. A2780/CP70+ch3 (s); A2780/CP70 (n n). Each data point represents the
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HCT-116+ch3 cells) for the minor groove binders, all three
compounds tested showed MMR deficiency-associated resistance
in both experimental systems used. The non-alkylating MGB PNU
151807 appears to be insensitive to the presence of MMR proteins.
This is, in our opinion, an interesting finding, due to the high
preclinical anti-tumour activity and the relatively low haemato-
logical toxicity shown for this compound (D’Alessio et al, 1994;
Ghielmini et al, 1997), and makes it a good future candidate for the
treatment of tumours responsive to MGB but presenting alter-
ations in the MMR pathway. As a collateral result we observed
that CDDP-resistant cell lines, CP70 and MCP1, are cross-
resistant to PNU 151807. However, this resistance is not associ-
ated with MMR deficiency, since there is no reversal of resistance
in CP70+ch3 cells to the PNU 151807, despite observed reversal
resistance for the three alkylating MGB. It must be noted that PNU
151807 is, like tallimustine, a derivative of the non-cytotoxic
compound, distamycin A (D’Alessio et al, 1994). Both PNU
151807 and tallimustine showed the same non-covalent DNA
interaction, as suggested by footprinting experiments reporting the
protection of the same AT-rich region in different DNA fragments
(Marchini et al, submitted for publication). The similar activity of
PNU 151807 in MMR-proficient and MMR-deficient cells is thus
likely to be solely due to the lack of alkylation produced by this
compound.
In conclusion, we have shown that some minor groove
alkylating agents are processed by the MMR system as has
previously been observed for major groove DNA binders. The
availability of an active, MMR deficiency-insensitive, non-
alkylating anti-tumour agent still binding in the minor groove,
could be an important alternative to the clinical use of MGB in
MMR-deficient tumours.
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